Kolexia
Ferru Aurelie
Oncologie médicale
Hôpital La Miletrie
Poitiers, France
63 Activités
0 Followers

Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs colorectales Instabilité des microsatellites Adénocarcinome Tumeurs du pancréas Métastase tumorale Tumeurs neuroendocrines Tumeurs du foie Thromboembolie Thromboembolisme veineux

Industries

Servier
7 collaboration(s)
Dernière en 2023
Amgen
6 collaboration(s)
Dernière en 2022
Ipsen
4 collaboration(s)
Dernière en 2023
Merck-Serono
3 collaboration(s)
Dernière en 2023

Dernières activités

Confounding mitigation for the exposure-response relationship of bevacizumab in colorectal cancer patients.
British journal of clinical pharmacology   10 décembre 2023
Circulating tumor DNA in unresectable pancreatic cancer is a strong predictor of first-line treatment efficacy: The KRASCIPANC prospective study.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver   10 juin 2023
A-140 MANAGEMENT OF NON-METASTATIC DUODENAL NEUROENDOCRINE TUMOURS
10th Conference of European Society of Endocrine Surgeons (ESES), Mainz, May 19-20, 2023   18 mai 2023
Perioperative Cetuximab with Cisplatin and 5-Fluorouracil in Esogastric Adenocarcinoma: A Phase II Study.
Cancers   06 avril 2023
LENVAGIST: A Multicentre, Comparative, Placebo-controlled, Double-blinded, Phase II Study of the Efficacy of Lenvatinib in Patients With Locally Advanced or Metastatic GIST After Failure of Imatinib and Sunitinib
Essai Clinique (Centre Léon-Bérard)   28 mars 2023
Cancérologie sur le site de Châtellerault : « un beau projet
CHU Poitiers   01 juillet 2022
Cancérologie sur le site de Châtellerault : « un beau projet
CHU Poitiers   01 juillet 2022
1472P Circulating tumor DNA in unresectable pancreatic cancer is a strong predictor of response to first-line therapy: The KRASCIPANC study
Abstract Book of the ESMO Congress 2021, 16 – 21 September 2021   01 septembre 2021
LBA41 Nivolumab (nivo) ± ipilimumab (ipi) in pre-treated patients with advanced, refractory pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine tumors (NECs) (GCO-001 NIPINEC)
Abstract Book of the ESMO Congress 2021, 16 – 21 September 2021   01 septembre 2021
481P Evaluation of serum mid-infrared spectroscopy as new prognostic marker for bevacizumab-based chemotherapy in first-line treatment of metastatic colorectal cancer
Abstract Book of the ESMO Congress 2021, 16 – 21 September 2021   01 septembre 2021